You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,415,348


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,415,348
Title:Nitrogenated derivatives of pancratistatin
Abstract: The present invention concerns nitrogenated derivatives of narciclasine and pancratistatin of the following general formula (I) as well their pharmaceutically acceptable salts. The present invention also concerns the use of these compounds in cancer therapy as well as a method for their preparation. ##STR00001##
Inventor(s): Marion; Frederic (Toulouse, FR), Annereau; Jean-Philippe (Toulouse, FR), Fahy; Jacques (Labruguiere, FR)
Assignee: Pierre Fabre Medicament (Boulogne-Billancourt, FR)
Application Number:13/055,947
Patent Claims:1. A compound of the following general formula (I): ##STR00052## or a pharmaceutically acceptable salt thereof, an isomer or a mixture of isomers in all proportions, in which: R.sub.1 represents a hydrogen atom or a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl, linear or branched C.sub.2 to C.sub.6 alkynyl, aryl or arylalkyl group, R.sub.2 represents a hydrogen atom, a saturated or unsaturated 3- to 7-membered hydrocarbon cycle, a 3- to 7-membered heterocycle or a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl, linear or branched C.sub.2 to C.sub.6 alkynyl, optionally substituted aryl, optionally substituted arylalkyl, C(O)R', SO.sub.2--R', C(O)OR', C(O)NHR', NH.dbd.CNHR', C(.dbd.NR''')R', C(S)R', C(S)OR', or C(S)NHR' group, where R' and R''' represent, independently of each other, a hydrogen atom, a saturated or unsaturated 3- to 7 membered hydrocarbon cycle, an optionally substituted 3- to 7-membered heterocycle, a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl, linear or branched C.sub.2 to C.sub.6 alkynyl, C.sub.1 to C.sub.6 hydroxyalkyl, C.sub.1 to C.sub.6 aminoalkyl, polyamine, polyether, optionally substituted aryl, optionally substituted arylalkyl or optionally substituted heteroaryl group, or R.sub.1 and R.sub.2 form together, with the nitrogen atom bearing them, an optionally substituted heteroaryl or a 3- to 7-membered heterocycle, which can comprise 1 to 3 additional heteroatoms, and optionally substituted with a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl, linear or branched C.sub.2 to C.sub.6 alkynyl, aryl, arylalkyl or heteroaryl group, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 represent, independently of each other, a hydrogen atom, a saturated or unsaturated 3- to 7-membered hydrocarbon cycle or a SO.sub.3H, PO.sub.3H.sub.2, C(O)OH, C(O)R'', C(O)OR'', C(O)NHR'', C(S)R'', C(S)OR'', C(S)NHR'' group, where R'' represents a hydrogen atom; a saturated or unsaturated 3- to 7-membered hydrocarbon cycle; a 3- to 7-membered heterocycle optionally substituted with a linear or branched C.sub.1 to C.sub.6 alkyl; a linear or branched C.sub.1 to C.sub.6 alkyl; linear or branched C.sub.2 to C.sub.6 alkenyl; linear or branched C.sub.2 to C.sub.6 alkynyl; C.sub.1 to C.sub.6 hydroxyalkyl; C.sub.1 to C.sub.6 aminoalkyl; optionally substituted polyamine; polyether; optionally substituted aryl; or optionally substituted heteroaryl group, or R.sub.3 and R.sub.1 together form a --CR.sub.8R.sub.9--, --SO.sub.2-- or --PO.sub.2H-- chain binding the oxygen atoms bearing them, R.sub.7 represents a hydrogen atom, a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl or linear or branched C.sub.2 to C.sub.6 alkynyl group or a saturated or unsaturated 3- to 7-membered hydrocarbon cycle, and R.sub.8 and R.sub.9 represent, independently of each other, a hydrogen atom or a linear or branched C.sub.1 to C.sub.6 alkyl group, such as a methyl.

2. The compound according to claim 1, wherein it meets the following formula (Ia): ##STR00053## for which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are as defined in claim 1.

3. The compound according to any one of claims 1 and 2, wherein R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 each represent a hydrogen atom.

4. The compound according to any one of claims 1 and 2, wherein R.sub.2 represents a group --C(O)R' with R' representing an aryl group, optionally substituted, and R.sub.1 is as defined in claim 1.

5. The compound according to any one of claims 1 and 2, wherein it is chosen among the following compounds: ##STR00054## ##STR00055## ##STR00056## ##STR00057## ##STR00058## ##STR00059## ##STR00060##

6. A pharmaceutical compound comprising at least one composition according to any one of claims 1 and 2 and at least one pharmaceutically acceptable excipient.

7. A pharmaceutical composition according to claim 6 which further comprises at least one active principle chosen from among anti-cancer agents including 6-mercaptopurine, fludarabine, cladribine, pentostatin, cytarabine, 5-fluorouracile, gemcitabine, methotrexate, raltitrexed, irinotecan, topotecan, etoposide, daunorubicin, doxorubicin, epirubicin, idarubicin, pirarubicin, mitoxantrone, chlormethine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, busulfan, carmustine, fotemustine, streptozocin, carboplatin, cisplatin, oxaliplatin, procarbazine, dacarbazine, bleomycin, vinblastine, vincristine, vindesine, vinorelbine, paclitaxel, docetaxel, L-asparaginase, flutamide, nilutamide, bicalutamide, cyproterone acetate, triptorelin, leuprorelin, goserelin, buserelin, formestane, aminoglutethimide, anastrozole, letrozole, tamoxifen, octreotide or lanreotide.

8. A method for preparing a compound according to any one of claims 1 and 2, wherein the compound of formula (I) is obtained by reaction of the compound of the following formula (II): ##STR00061## for which R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are as defined in claim 1, and wherein the method comprises the following successive steps: (i) hydrogenolysis of the azide of the compound of formula (II) as defined above in to free amine to yield a compound of formula (I) for which R.sub.1.dbd.R.sub.2.dbd.H, (ii) optionally one or several substitution steps of the free amine obtained in the preceding step (i) to yield a compound of formula (I) for which at least one of the R.sub.1 and R.sub.2 groups does not represent a hydrogen atom, and (iii) separation from the reaction medium of the compound of formula (I) obtained in the preceding step (i) or (ii).

9. The method according to claim 8, wherein in the case of a compound of formula (I), for which R.sub.1 and R.sub.2 together form, with the nitrogen atom bearing them, a 1,2,3-triazole optionally substituted with a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl, linear or branched C.sub.2 to C.sub.6 alkynyl, aryl, arylalkyl or heteroaryl group, the method comprises the following successive steps: (i) cycloaddition of the azide of the compound of formula (II) as defined in claim 12 with an alkyne of formula A-C.ident.CH, for which A represents a hydrogen atom or a linear or branched C.sub.1 to C.sub.6 alkyl, linear or branched C.sub.2 to C.sub.6 alkenyl, linear or branched C.sub.2 to C.sub.6 alkynyl, aryl or heteroaryl group, and (ii) separation from the reaction medium of the compound of formula (I) obtained in the preceding step (i).

10. The method according to any one of claims 8 and 9, wherein the compound of formula (II) as defined in claim 8, for which the N.sub.3 group is located on the same side of the cycle as the OR.sub.3 group, is obtained by nucleophile substitution with a mineral azide of the compound of the following formula (III): ##STR00062## for which R.sub.3, R.sub.4, R.sub.6 and R.sub.7 are as defined in claim 1 and X represents a --SO--, --SO.sub.2-- or --CO-- group.

11. A compound of the following formula (II): ##STR00063## or a pharmaceutically acceptable salt thereof, an isomer or a mixture of isomers in all proportions in which R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are as defined in claim 1.

12. The compound according to claim 11, wherein it meets the following formula: ##STR00064##

13. The compound according to claim 1, wherein the mixture of isomers is a mixture of enantiomers.

14. The compound of claim 13, wherein the mixture of enantiomers is a racemate mixture.

15. The compound according to claim 1, wherein R.sub.8 and R.sub.9 represent, independently of each other, a hydrogen atom or a methyl group.

16. The compound according to claim 4, wherein R.sub.2 represents a group --C(O)R' with R' representing a phenyl group optionally substituted.

17. The compound according to claim 4, wherein R.sub.1 represents a hydrogen atom.

18. The method according to claim 10, wherein X represents a --SO.sub.2-- group.

19. The compound according to claim 11, wherein the mixture of isomers is a mixture of enantiomers.

20. The compound of claim 19, wherein the mixture of enantiomers is a racemate mixture.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.